Mucormycosis  in COVID-19 - Evaluation of associated risk factors at a tertiary care   centre.

Pragathi Kottapalli; Srinivas Kishore Sistla; SivaRam Nunna; Naveen Chander Reddy Podduturi; Sadhana Yelamanchili Veturi; Naveen Admala; Aswini Deborah

doi:10.5455/IJMRCR.172-1660903934

2023, Vol: 7, Issue: 11

7 / 11Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Copyright Transfer Form

« Previous Article

Original Research
Online Published: 21 Nov 2022

Int J Med Rev Case Rep. 2022; 6(15): 79-85

doi: 10.5455/IJMRCR.172-1660903934

Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.

Pragathi Kottapalli, Srinivas Kishore Sistla, SivaRam Nunna, Naveen Chander Reddy Podduturi, Sadhana Yelamanchili Veturi, Naveen Admala, Aswini Deborah.

Abstract
Aim: India has reported a recent surge in Mucormycosis cases. Prevention of COVID-19 associated Mucormycosis needs to focus on aiming for better glycemic control in COVID-19 patients and monitoring the use of systemic corticosteroids in treating severe cases. This study is an attempt to evaluate various patient characteristics that could contribute to Mucormycosis among COVID and post COVID patients.
Materials and Methods: A retrospective observational study was carried out at a tertiary Care Hospital during April 2021–June 2021. After obtaining approval from Institutional Ethics committee, various demographic and clinical details of all patients, such as diabetes mellitus, use of steroids in COVID-19 treatment, use of immunosuppressant drugs, oxygen therapy etc., were noted. All Mucormycosis patients were treated with Amphotericin B and aggressive surgical treatment.
Results: In the present study, majority of the patients who developed COVID associated Mucormycosis were treated in Private Hospitals (65, 62.5 %) for COVID -19 disease . About 78.89 % of Mucormycosis patients were males. In majority of the patient’s onset of symptoms of Mucormycosis was seen during the first week (56 %).Most patients were between 51-60 years (32.1 %). Among risk factors, 91.7 % had COVID-19 infection, 90.47% had received steroids, 80 % had diabetes mellitus and 47.11 % had received oxygen. About 37 % of patients presented in stage III and 35 % presented in stage I and II. In our study mortality was very less compared to other studies ( 12.35 %.).
Conclusion: There is a complex association between COVID -19 and Mucormycosis.The main predisposing factor was use of steroids during the treatment of COVID-19 which led to uncontrolled diabetes mellitus predisposing to Mucormycosis.

Key words: COVID – 19, Mucormycosis, Rhino Orbital Cerebral Mucormycosis, Diabetes

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Pragathi Kottapalli Articles by Srinivas Kishore Sistla Articles by SivaRam Nunna Articles by Naveen Chander Reddy Podduturi Articles by Sadhana Yelamanchili Veturi Articles by Naveen Admala Articles by Aswini Deborah
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Kottapalli P, Sistla SK, Nunna S, Podduturi NCR, Veturi SY, Admala N, Deborah A. Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. Int J Med Rev Case Rep. 2022; 6(15): 79-85. doi:10.5455/IJMRCR.172-1660903934

Web Style

Kottapalli P, Sistla SK, Nunna S, Podduturi NCR, Veturi SY, Admala N, Deborah A. Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. https://www.mdpub.net/?mno=107346 [Access: October 13, 2024]. doi:10.5455/IJMRCR.172-1660903934

AMA (American Medical Association) Style

Kottapalli P, Sistla SK, Nunna S, Podduturi NCR, Veturi SY, Admala N, Deborah A. Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. Int J Med Rev Case Rep. 2022; 6(15): 79-85. doi:10.5455/IJMRCR.172-1660903934

Vancouver/ICMJE Style

Kottapalli P, Sistla SK, Nunna S, Podduturi NCR, Veturi SY, Admala N, Deborah A. Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. Int J Med Rev Case Rep. (2022), [cited October 13, 2024]; 6(15): 79-85. doi:10.5455/IJMRCR.172-1660903934

Harvard Style

Kottapalli, P., Sistla, . S. K., Nunna, . S., Podduturi, . N. C. R., Veturi, . S. Y., Admala, . N. & Deborah, . A. (2022) Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. Int J Med Rev Case Rep, 6 (15), 79-85. doi:10.5455/IJMRCR.172-1660903934

Turabian Style

Kottapalli, Pragathi, Srinivas Kishore Sistla, SivaRam Nunna, Naveen Chander Reddy Podduturi, Sadhana Yelamanchili Veturi, Naveen Admala, and Aswini Deborah. 2022. Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. International Journal of Medical Reviews and Case Reports, 6 (15), 79-85. doi:10.5455/IJMRCR.172-1660903934

Chicago Style

Kottapalli, Pragathi, Srinivas Kishore Sistla, SivaRam Nunna, Naveen Chander Reddy Podduturi, Sadhana Yelamanchili Veturi, Naveen Admala, and Aswini Deborah. "Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.." International Journal of Medical Reviews and Case Reports 6 (2022), 79-85. doi:10.5455/IJMRCR.172-1660903934

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Kottapalli, P., Sistla, . S. K., Nunna, . S., Podduturi, . N. C. R., Veturi, . S. Y., Admala, . N. & Deborah, . A. (2022) Mucormycosis in COVID-19 - Evaluation of associated risk factors at a tertiary care centre.. International Journal of Medical Reviews and Case Reports, 6 (15), 79-85. doi:10.5455/IJMRCR.172-1660903934

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.

For best results, please use Internet Explorer or Google Chrome.

Contact Information

Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31, Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press.

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500

About International Journal of Medical Reviews and Case Reports

Contact Information

How to cite this article